Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Cancer and immune response: old and new evidence for future challenges.

de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, Codes-Manuel de Villena ME.

Oncologist. 2008 Dec;13(12):1246-54. doi: 10.1634/theoncologist.2008-0166. Epub 2008 Dec 4. Review.

2.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951
3.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
4.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
5.

Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.

Frey AB, Monu N.

J Leukoc Biol. 2006 Apr;79(4):652-62. Epub 2006 Jan 13. Review.

PMID:
16415165
6.

Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.

Agarwala SS, Ribas A.

J Immunother. 2010 Jul-Aug;33(6):557-69. doi: 10.1097/CJI.0b013e3181dcd260. Review.

PMID:
20551840
7.

Immune suppression in the tumor microenvironment.

Gajewski TF, Meng Y, Harlin H.

J Immunother. 2006 May-Jun;29(3):233-40. Review.

PMID:
16699366
8.

Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?

Salih HR, Nüssler V.

Eur J Med Res. 2001 Aug 27;6(8):323-32. Review.

PMID:
11549514
9.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

10.

Escape from host-antitumor immunity.

Pawelec G, Zeuthen J, Kiessling R.

Crit Rev Oncog. 1997;8(2-3):111-41. Review.

PMID:
9570292
11.

Cytokine gene-mediated immunotherapy: current status and future perspectives.

Jinushi M, Tahara H.

Cancer Sci. 2009 Aug;100(8):1389-96. doi: 10.1111/j.1349-7006.2009.01202.x. Epub 2009 May 13. Review.

12.

Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.

Atreya I, Neurath MF.

Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72. doi: 10.1586/14737140.8.4.561. Review.

PMID:
18402523
13.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
14.

Immune resistance orchestrated by the tumor microenvironment.

Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H.

Immunol Rev. 2006 Oct;213:131-45. Review.

PMID:
16972901
15.

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V.

Immunol Rev. 2008 Apr;222:162-79. doi: 10.1111/j.1600-065X.2008.00602.x. Review.

PMID:
18364001
16.

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.

Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F.

Cancer Immunol Immunother. 2008 Nov;57(11):1579-87. doi: 10.1007/s00262-008-0505-6. Epub 2008 Mar 28. Review.

PMID:
18369619
17.

CTLA-4: negative regulator of the immune response and a target for cancer therapy.

Keilholz U.

J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe. Review.

PMID:
18463542
18.

Regulatory T cells: major players in the tumor microenvironment.

Beyer M, Schultze JL.

Curr Pharm Des. 2009;15(16):1879-92. Review.

PMID:
19519430
19.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Maccalli C, Scaramuzza S, Parmiani G.

Cancer Immunol Immunother. 2009 May;58(5):801-8. doi: 10.1007/s00262-008-0635-x. Epub 2008 Dec 17. Review.

PMID:
19089424
20.

Capitalizing on the immunogenicity of dying tumor cells.

Fonseca C, Dranoff G.

Clin Cancer Res. 2008 Mar 15;14(6):1603-8. doi: 10.1158/1078-0432.CCR-07-2245. Review.

Supplemental Content

Support Center